Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™ Butterfly Network, Inc. a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced the appointment of David Horsley, Ph.D. as Senior Vice President…
Obesity Drug Olatorepatide, Licensed by Regeneron Pharmaceuticals, Shows Positive Phase 3 Outcomes in Chinese Patients Regeneron Pharmaceuticals, Inc. today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the…
Novo Nordisk broadens U.S. patient access to FDA-approved semaglutide treatments through Hims & Hers following a strategic shift in its U.S. GLP-1 business approach. Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that…
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed or Refractory Multiple Myeloma Halozyme Therapeutics has announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for the use of TECVAYLI (teclistamab-cqyv)…
NEJM Publishes Phase III ALLEGORY Results Showing Gazyva Reduces Disease Activity in Common Lupus Genentech, a member of the Roche Group, has announced that detailed results from the Phase III ALLEGORY clinical trial evaluating Gazyva (obinutuzumab) in adults with Systemic…
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia DiaMedica Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that…
Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon™ peptide platform to…
ImmunoScape Announces Memorandum of Understanding for Clinical Trial with Premier U.S. Cancer Center ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, today announced the execution of a Memorandum of…
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially…
Innovate 32 Partners with Crestview Dental and Cedar Street Family Dentistry, Continuing Momentum in East Tennessee Innovate 32 a growth-oriented dental services organization, today announced new partnerships with Crestview Dental and Cedar Street Family Dentistry, two highly respected general dentistry…
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the…
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) Esperion and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema…